MapLight Therapeutics Inc

MapLight Therapeutics Inc(MPLT)の株価予測

$13.310

+0.349 (+2.62%)終値時点

価格予想

1-Day Price Prediction
-3.38%
1-Week Prediction
-8.64%
1-Month Prediction
2026 Prediction
2030 Prediction

アプリで開くと、より長期の予想を確認できます。

Loading chart…

類似チャート分析による MPLT の予測・予想

Alphio's MPLT stock price prediction model matches the current MapLight Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $12.86 (-3.38%). The 1-week path is $12.16 (-8.64%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

MapLight Therapeutics Inc 株は買うべき?

MapLight Therapeutics, Inc. is a good buy right now due to its current price of $12.6, which is significantly below the recent analyst price target of $25 from Craig-Hallum. The stock has shown a strong recent performance with a 5-day change of +12.40%, indicating positive momentum. However, investors should be cautious of the risk posed by the negative sentiment surrounding the Phase 2 trial results, which have led to downgrades and a projected EPS of -1.32 for the last earnings report, reflecting ongoing financial challenges.

MPLT の株価は Tuesday に $13.31 で引け、その前に上昇 +2.62%

MapLight Therapeutics Inc (MPLT) last closed at $13.31, gaining +2.62%. These facts feed the 1-day and 1-week MPLT price prediction above.

予想の要因

MapLight Therapeutics Inc(MPLT)の予想は、類似したチャートパターン・季節性・移動平均を組み合わせています。

Similar patterns

Positive

Bullish

Seasonality

Negative

Bearish

SMA 20

Positive

Bullish

SMA 200

Negative

Bearish

類似チャートパターン

直近の値動きが MPLT に最も近い銘柄を、類似度順に表示します。

MPLT の季節性分析

Historically the probability of a positive September return for MPLT is 0.00%. March offers the highest probability of a positive month at 100.00%, while August is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.

Loading chart…

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める